Lead time associated with screening for prostate cancer

被引:66
作者
Törnblom, M [1 ]
Eriksson, H
Franzén, S
Gustafsson, O
Lilja, H
Norming, U
Hugosson, J
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Surg Sci Ctr, Dept Urol, S-14186 Huddinge, Sweden
[2] Sahlgrens Univ Hosp, Dept Internal Med, S-41345 Gothenburg, Sweden
[3] Sahlgrens Univ Hosp, Dept Urol, S-41345 Gothenburg, Sweden
[4] Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Clin Chem, Malmo, Sweden
[5] Mem Sloan Kettering Canc Ctr, Dept Clin Labs Urol & Med, New York, NY 10021 USA
[6] S Gen Hosp, Dept Urol, Stockholm, Sweden
关键词
prostate cancer; lead time; prostate-specific antigen; diagnosis; epidemiology;
D O I
10.1002/ijc.11554
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Screening serum levels of prostate-specific antigen (PSA) is now a major strategy for early detection of prostate cancer (PC). Quantification of the lead time thus obtained is important both for understanding the development of PC and for evaluating the advantages and disadvantages of widespread screening. In our study, 1,233 randomly selected men living in Stockholm in 1988 were invited to participate in an early detection (ED) program, in which suspicious findings provided by digital rectal examination (DRE), transrectal ultrasonography (TRUS) and/or a PSA value greater than or equal to10.0 ng/mL were followed up by biopsy. The cumulative incidence (Kaplan-Meier) of PC in the 946 participants (ED) during 12 years of follow-up was compared to that of an age-matched, randomly selected reference population (RP) of 657 men for whom PSA values (from frozen serum samples) could also be obtained. The PC incidence in men in the RP with PSA values >3.0 ng/mL reached the corresponding level for the ED group after 10.6 years (the "catch-up" point). After 12 years of follow-up, the estimated median lead time for men with PSA values in this interval was 4.5 years in the ED population, compared to 7.8 years in the RP. With 20 years of follow-up, the estimated median lead time of the RP was enhanced to 10.7 years. The lead time in connection with PC was influenced by the initial PSA level (although with large variations), length of follow-up and sensitivity of the ED procedure employed. The ED program described here was not associated with major overdetection. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:122 / 129
页数:8
相关论文
共 31 条
[1]   Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration [J].
Alexander, EE ;
Qian, JQ ;
Wollan, PC ;
Myers, RP ;
Bostwick, DG .
UROLOGY, 1996, 47 (05) :693-698
[2]   Lead-time in prostate cancer screening (Finland) [J].
Auvinen, A ;
Määttänen, L ;
Stenman, UH ;
Tammela, T ;
Rannikko, S ;
Aro, J ;
Juusela, H ;
Hakama, M .
CANCER CAUSES & CONTROL, 2002, 13 (03) :279-285
[3]   Should we start population screening for prostate cancer? Randomised trials are still needed [J].
Auvinen, A ;
Alexander, FE ;
de Koning, HJ ;
Miller, AB .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (03) :377-378
[4]   Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria [J].
Bartsch, G ;
Horninger, W ;
Klocker, H ;
Reissigl, A ;
Oberaigner, W ;
Schönitzer, D ;
Severi, G ;
Robertson, C ;
Boyle, P .
UROLOGY, 2001, 58 (03) :417-424
[5]   MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER [J].
CATALONA, WJ ;
SMITH, DS ;
RATLIFF, TL ;
DODDS, KM ;
COPLEN, DE ;
YUAN, JJJ ;
PETROS, JA ;
ANDRIOLE, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1156-1161
[6]   COMPARISON OF DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE-SPECIFIC ANTIGEN IN THE EARLY DETECTION OF PROSTATE-CANCER - RESULTS OF A MULTICENTER CLINICAL-TRIAL OF 6,630 MEN [J].
CATALONA, WJ ;
RICHIE, JP ;
AHMANN, FR ;
HUDSON, MA ;
SCARDINO, PT ;
FLANIGAN, RC ;
DEKERNION, JB ;
RATLIFF, TL ;
KAVOUSSI, LR ;
DALKIN, BL ;
WATERS, WB ;
MACFARLANE, MT ;
SOUTHWICK, PC .
JOURNAL OF UROLOGY, 1994, 151 (05) :1283-1290
[7]   SIMPLIFIED MODELS OF SCREENING FOR CHRONIC DISEASE - ESTIMATION PROCEDURES FROM MASS-SCREENING PROGRAMS [J].
DAY, NE ;
WALTER, SD .
BIOMETRICS, 1984, 40 (01) :1-14
[8]   Prostate cancer mortality reduction by screening:: Power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial [J].
de Koning, HJ ;
Liem, MK ;
Baan, CA ;
Boer, R ;
Schröder, FH ;
Alexander, FE .
INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (02) :268-273
[9]   Large-scale randomized prostate cancer screening trials:: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial [J].
de Koning, HJ ;
Auvinen, A ;
Sanchez, AB ;
da Silva, FC ;
Ciatto, S ;
Denis, L ;
Gohagan, JK ;
Hakama, M ;
Hugosson, J ;
Kranse, R ;
Nelen, V ;
Prorok, PC ;
Schröder, FH .
INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (02) :237-244
[10]   A PROSPECTIVE EVALUATION OF PLASMA PROSTATE-SPECIFIC ANTIGEN FOR DETECTION OF PROSTATIC-CANCER [J].
GANN, PH ;
HENNEKENS, CH ;
STAMPFER, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (04) :289-294